PAPER Citrome L
CNS Drugs. 2013 Nov;27(11):879-911. PubMed: 24062193
PAPER Giaccone G, Giaccone G, DiFede G, Giovagnoli AR, Tagliavini F
Alzheimers Dement. 2008;4(S2):T590
PAPER Gallo M, Tomaino C, Bernardi L, Maletta R, Anfossi M, Geracitano S, Vasso F, Puccio G, Colao R, Frangipane G, Mirabelli M, Smirne N, Muraca MG, De Vito O, Bruni AC
Alzheimers Dement. 2008;4(S2):T585
PAPER Piscopo P, Talarico G, Spadoni O, Malvezzi-Campeggi L, Crestini A, Gasparini M, Vanacore N, Lenzi GL, Pocchiari M, Confaloni A, Bruno G
Alzheimers Dement. 2008;4(S2):T595.
PAPER Sorbi S, Tedde A, Nacmias B, Ciantelli M, Caffarra P, Ghidoni E, Bracco L, Piccini C
Neurobiol Aging. 2002 Jul-Aug;23(1S):312.
PAPER Clarimón J, Guerreiro R, Lleó A, Guardia C, Blesa F, Gómez-Isla T, Boada M, Bullido MJ, Ferrer I, Martínez-Lage P, Masdeu J, Molina L, Molinuevo JL, Pastor P, Pérez-Tur J, Rey MJ, Sánchez-Valle R, Tàrraga L, Valdivieso F, Singleton A, Hardy J
Alzheimers Demen. 2008 Jul;4(4 Suppl):T583.
PAPER Hunt L
PharmacoEconomics & Outcomes News. 422: 3-4, 2003 Jul 26
RESEARCH NEWS 2013-11-21 Research News The U.S. Food and Drug Administration on October 25 approved a second amyloid imaging agent. Flutemetamol, renamed Vizamyl, is an F18-labeled ligand developed by GE Healthcare. It joins florbetapir, or Amyvid, developed by Avid Pharmaceutica
PAPER Zu T, Liu Y, Bañez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, Ostrow LW, Rothstein JD, Troncoso JC, Ranum LP
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4968-77. Epub 2013 Nov 18 PubMed: 24248382
PAPER Hardy J, Rogaeva E
Exp Neurol. 2013 Nov 15; PubMed: 24246281
PAPER Phillipson OT
Neurobiol Aging. 2014 Apr;35(4):847-57. Epub 2013 Oct 10 PubMed: 24246717
PAPER Wu AG, Wong VK, Xu SW, Chan WK, Ng CI, Liu L, Law BY
Int J Mol Sci. 2013 Nov 15;14(11):22618-41. PubMed: 24248062
PAPER He Q, Yu W, Wu J, Chen C, Lou Z, Zhang Q, Zhao J, Wang J, Xiao B
PLoS One. 2013;8(11):e78418. Epub 2013 Nov 8 PubMed: 24250796